To increase the documentation about the need for supplemental birth control following the administration of sugammadex in women on hormonal contraception from a baseline of 3% to 40% at the Moses, Weiler, and Hutchinson Campus sites by June 21st, 2019.

Sugammadex is the reversal agent for neuromuscular blockade after administration of Rocuronium or Vecuronium. Administration of Sugammadex has been shown to interact with hormonal based contraceptives rendering them less effective -- specifically through reduction of free plasma concentration of progestin.

If a patient on hormonal based contraception during the perioperative period receives sugammadex, the patient must use an additional, non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days.

The use of Sugammadex in the perioperative setting is increasing rapidly. However, there is little documentation in regards to counseling patients who are on hormonal contraception to use other forms of contraception.

Extensive review of 1086 EPIC charts on patients who received sugammadex at Moses, Hutch, and Weiler campus sites only 3% of the patients charts had documented counseling after sugammadex use.

We achieved our goal!

We will continue to keep Epic pop up as well as sugammadex labels in machine carts to help facilitate reminders for PACU providers.

Sugammadex is being used at a rapidly increasing rate as part of anesthetic techniques. Over the course of 2 PDSA cycles, we were able to increase the documentation about the need for supplemental birth control following the administration of sugammadex in women on hormonal contraception from 3% to 46.7% at the Moses, Weiler, and Hutch campuses, thereby achieving our AIM statement.

**PDSA Cycle #1**
- **PLAN:** Increase documentation to use alternative contraception after sugammadex with EPIC pop up reminders.
- **DO:** Install EPIC pop up reminder about need for counseling/documentation if sugammadex is given before chart is closed and send departmental email regarding update.
- **STUDY:** Data collection and analysis of charts of women ages 18-50 that received sugammadex at Hutch, Moses and Weiler campuses from February 1st to April 1st.
- **Total cases reviewed:** 123
- **Total cases applicable:** 80
  - 43 cases were excluded
    - patients were postmenopausal
    - patients were s/p sterilization procedure
    - patients were not on hormonal contraception
- **Total cases with proper counseling documentation:** 25

**PDSA Cycle #2**
- **PLAN:** Increase documentation by applying a label to the patient’s chart to inform PACU provider of the need to counsel and document conversation of discussion prior to discharge.
- **DO:** Generate labels for each OR suite. Send email to department asking intraoperative providers to place label on patient’s chart if discussion by PACU provider is warranted.
- **STUDY:** Data collection and analysis of charts of women ages 18-50 that received sugammadex at Hutch, Moses and Weiler campuses from May 28th to June 21st.
- **Total cases reviewed:** 66
- **Total cases applicable:** 30
  - 36 cases were excluded
    - patients were postmenopausal
    - patients were s/p sterilization procedure
    - patients were not on hormonal contraception
- **Total cases with proper counseling documentation:** 14